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Extracellular Matrix and Cytokines: A Functional Unit
ELKE SCHONHERR* and HEINZ-J(RGEN HAUSSER
Institute ofPhysiological Chemistry and Pathobiochemistry University ofMiinster, Waldeyerstrasse 15, D-48149 Miinster, Germany
The extracellular matrix (ECM) as well as soluble mediators like cytokines can influence the
behavior of cells in very distinct as well as cooperative ways. One group of ECM molecules
which shows an especially broad cooperativety with cytokines and growth factors are the pro-
teoglycans. Proteoglycans can interact with their core proteins as well as their gly-
cosaminoglycan chains with cytokines. These interactions can modify the binding of
cytokines to their cell surface receptors or they can lead to the storage of the soluble factors in
the matrix. Proteoglycans themselves may even have cytokine activity. In this review we
describe different proteoglycans and their interactions and relationships with cytokines and
we discuss in more detail the extracellular regulation of the activity of transforming growth
factor-13 (TGF-) by proteoglycans and other ECM molecules. In the third part the interaction
of heparan sulfate chains with fibroblast growth factor-2 (FGF-2, basic FGF) as a prototype
example for the interaction of heparin-binding cytokines with heparan sulfate proteoglycans
is presented to illustrate the different levels of mutual dependence of the cytokine network
and the ECM.
Keywords: proteoglycan, glycosaminoglycan, TGF-, FGF-2
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mal growth factor, FGF-2, fibroblast growth factor-2, GAG, glycosaminoglycan, GPI, glycosyl phos-
phatidy inositol, LAP, latency associated protein, LTBP, latent TGF- binding protein, PDGF,
platelet-derived growth factor, PG-100, proteoglycan-100, TGF-, transforming growth factor-
INTRODUCTION
During the last few years it has become more and
more apparent that the biological activities of
cytokines can not be sufficien.tly described by their
interactions with the corresponding signaling recep-
tors alone. Instead, it appears that in many, if not most
cases cytokines and the extracellular matrix (ECM)
cooperate in forming an "information network" that
regulates such fundamental processes as cell prolifer-
ation, differentiation and apoptosis.
The ECM is a complex supramolecular structure
composed of different types of macromolecules
which are predominantly linked by non-covalent
bonds. The major constituents are the collagens, the
non-collagenous glycoproteins, elastin, hyaluronan
and the proteoglycans. With the exception of elastin
(and hyaluronan), all the other classes consist of dif-
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ferent families of related proteins which are derived
from individual genes. They can be expressed in a tis-
sue specific and developmentally distinct manner and
can therefore form matrices with particular physical
as well as biological properties which are tailored for
their distinct biological functions as well as for spe-
cific interactions with the embedded cells. These
interactions are mediated by cell surface receptors for
matrix proteins which can be integrins (Hynes, 1992)
or non-integrin-receptors (Shrivastava et al., 1997).
The activation of these receptors by the ECM can
influence the intracellular signal transduction and the
expression of genes. By these means the matrix
directly participates in the control of cell proliferation
and differentiation as well as the survival of the cells
(Frisch and Ruoslahti, 1997).
Another important factor in the control of cell
behaviour are soluble mediators like cytokines. For
the purpose of this review we want to use this term
not only for the classical cytokines but also for
growth factors, because similar rules apply for their
interactions with ECM molecules. The relationships
between cytokines and the extracellular matrix are
manyfold. (1) Cytokines can influence the expression
(Kovacs and DiPietro, 1994; Grande et al., 1997) and
the turnover (Galis et al., 1994; 1995) of specific
ECM molecules. (2) Certain matrix derived peptides
can mediate the synthesis of cytokines (Lopez-Mor-
atalla et al., 1995). (3) Cytokines can be dependent on
ECM molecules as co-receptors (Rapraeger et al.,
1991; Yayon et al., 1991) or (4) matrix cell surface
receptors like integrins may be needed for the cluster-
ing of cytokine receptors to cause an effective signal
transduction (Schneller et al., 1997). (5) Cytokines
can use intracellular signal transduction pathways that
are similar to the ways activated by matrix receptors
(Schlaepfer et al., 1994; Short et al., 1998). (6) Some
cytokines can directly bind to specific ECM constitu-
ents whereby their effects are localized to specific
areas and/or they may be stored in the matrix for later
release. In this review proteoglycans as the principal
mediators ofECM cytokine interactions will be intro-
duced and the interplay between these two systems
will be characterized more closely in two well studied
examples, TGF- and FGF-2.
PROTEOGLYCANS
Most of the interactions of cytokines with ECM mole-
cules are mediated by proteoglycans. Proteoglycans
are a heterogenous group of macromolecules charac-
terized by at least one glycosaminoglycan (GAG)
chain attached to a core proteins. GAG chains are
unbranched, acidic heteropolysaccharides consisting,
in principle, of repeating disaccharide units. On the
basis of the constituting disaccharide units, three dif-
ferent types of sulfated GAGs can be distinguished:
(1) chondroitin/dermatan sulfate, (2) heparan sul-
fate/heparin and (3) keratan sulfate. The backbone of
chondroitin sulfate chains is built by disaccharide
units of N-acetyl galactosamine and glucuronic acid
residues that can be sulfated in the C4- and/or
C6-position of the N-acetyl galactosamine residues.
In dermatan sulfate the glucuronic acid is additionally
epimerized to iduronic acid. The initial polysaccha-
ride backbone of heparan sulfate and heparin consists
of alternating N-acetyl glucosamine and glucuronic
acid residues. This structure subsequently becomes
modified by a series of reactions, each one creating
the substrate structure for the next modifying step.
The first modification is N-deacetylation and subse-
quent N-sulfation of N-acetyl glucosamine residues,
both reactions being carried out by the same enzyme.
In heparan sulfate these reactions are restricted to
characteristic domains, leaving parts of the chain
essentially unmodified, whereas in heparin these
modifications run more towards completion. Subse-
quent modifications include the epimerization of glu-
curonic acid to iduronic acid, the sulfation of 20 of
glucuronic acid (rare) and iduronic acid residues and
the sulfation of 60 and 30 (rare) of glucosamine resi-
dues. The consequence of the incompleteness of each
modifying step is the generation of an enormous
structural heterogeneity in the modified domains ’of
the heparan sulfate chain, leading to the potential for a
great variety of specific interactions (Hardingham and
Fosang, 1992). Finally, keratan sulfate chains are
composed of alternating N-acetyl glucosamine and
galactose residues that can be O-sulfated at C6 of
either sugar (Fig. 1).EXTRACELLULAR MATRIX AND CYTOKINES 91
TABLE Classification of Proteoglycans
Cell associatedproteoglycans Matrix associatedproteoglycans
Proteoglycans with transmembrane domains:
Syndeeansa:
Syndecan- (Syndecan)
Syndecan-2 (Fibr’oglycan)
Syndecan-3 (N-Syndecan)
Syndecan-4 (Ryudocan, Amphiglycan)
others:
Betaglycan (TGF-l-Receptor III)
NG2
CD44
Proteoglycans with glycolipid-anchors:
Giypieansa:
Glypican- (Glypican)
Glypican-2 (Cerebroglycan)
Glypican-3 (OCI-5)
Glypican-4 (K-Glypican)
Glypican-5
Glypican-6
Large proteoglycans:
Proteoglycans of the basal lamina:
Perlecan
Agrin
Bamacan
Proteoglycans of the aggrecan-familya:
Aggrecan
Versican
Neurocan
Brevican
others:
Collagens, Type IX, XII, XIV, XVIII
Testican
Phosphacan
Small proteoglycans:
Leucine-rich repeat proteoglycans:
Decorin
Biglycan
Fibromodulin
Lumican
PRELP
Keratocan
Epiphycan (PG-Lb)
Mimecan (Osteoglycin)
others:
PG-100/CSF- (M-CSF)
a. Proteoglycans, mentioned in the text.
There are many different types of proteoglycan
core proteins in vertebrates. A complete discussion of
all the different molecules and their proposed func-
tions would be beyond the scope of this review.
Therefore, only those proteoglycans which have been
implicated in interactions with cytokines shall be
described in more detail (Table I). In general, prote-
oglycans can be classified in cell associated mole-
cules and matrix associated molecules. Some cell
associated proteoglycans are inserted into the plasma
membrane by a transmembrane domain, as are the
members of the syndecan family (Carey, 1997),
betaglycan (Lopez-Casillas et al., 1991), the prote-
oglycan NG2 (Nishiyama et al., 1991) and CD44
(Lesley et al., 1997). In contrast, members of the gly-
pican family are anchored in the membrane via a gly-92 ELKE SCHONHERR and HEINZ-JORGEN HAUSSER
cosyl phosphatidyl inositol (GPI) moiety (Lander et
al., 1996).
Almost all cells possess at their surface mem-
brane-associated heparan sulfate proteoglycans that
belong either to the syndecan or to the glypican fam-
ily. In addition, betaglycan and certain splice variants
of CD44 can carry heparan sulfate chains. Via their
heparan sulfate chains, these molecules are able to
interact with a variety of extracellular ligands, such as
cytokines and growth factors, molecules of the sur-
rounding extracellular matrix, or surface proteins of
neighboring cells. Simultaneous binding of growth
factors/cytokines to heparan sulfate chains and to the
respective signaling receptor is the basis of the dual
receptor theory for cytokine signaling that has origi-
nally been described for fibroblast growth factor-2
(FGF-2 or bFGF, Yayon et al., 1991; Rapraeger et al.,
1991). However, the underlying principle appears to
be valid for numerous other growth factors and
cytokines as well (Selleck, 1998).
In addition to GAG mediated interactions, some of
the membrane-associated proteoglycans have been
shown to bind ligands specifically via their core pro-
teins. Even though transforming growth factor-
(TGF-) can interact with heparan sulfate chains,
binding of TGF- to betaglycan is mediated by the
core protein of this proteoglycan (Andres et al.,
1992). TGF- bound to the betaglycan core protein
can be presented to the TGF-I type II receptor which
is involved in signal transduction (Lopez-Casillas et
al., 1993). Another example is provided by the chon-
droitin sulfate proteoglycan NG2, which modulates
the biological activity of platelet-derived growth fac-
tor AA (PDGF-AA) by interacting with the PDGF-a
receptor (Grako and Stallcup, 1995). Indeed, NG2 has
to be present for effective signal transduction via the
PDGF-o receptor, as this receptor cannot be auto-
phosphorylated in cells from NG2 (-/-) mice (Grako
et al., 1999).
The matrix associated proteoglycans can be classi-
fied according to size, distribution and sequence simi-
larities of their core proteins (Table I). Perlecan and
agrin are large modular proteoglycans which are inte-
grating constituents of basement membranes. The
modular structure of their core proteins allows them
to interact with a variety of other components of the
basement membrane, thus contributing to the struc-
tural integrity of this specialized type of ECM. With
the negative charge of their heparan sulfate chains,
they contribute to the charge selectivity of the glomer-
ular basement membrane. Additionally, these chains
can interact with heparin-binding cytokines, mediat-
ing storage of these cytokines in the ECM (Iozzo,
1994).
Another group of large matrix associated prote-
oglycans, that are not constituents of basement mem-
branes, are the members of the aggrecan family:
aggrecan, versican, neurocan and brevican. They pos-
sess a binding site for hyaluronan at the N-terminus of
their core protein and a lectin-like domain at the
C-terminus. Therefore, they are suited to form a link
between hyaluronan in the ECM and glycoproteins
and glycolipids on the cell surface (Miura et al.,
1999). In addition, they contain EGF-like domains
which have been shown to mediate cell proliferation
in fibroblasts (Zhang et al., 1998). Apparently, these
matrix molecules exhibit cytokine-like activities by
themselves.
The largest group of the matrix associated prote-
oglycans are the small leucine-rich repeat proteogly-
cans. Eight different members of this family have
been described so far. As in other proteins containing
the leucine-rich repeat motif, this structure is
expected to mediate protein-protein interactions in
these proteoglycans, too (Kresse et al., 1993; Iozzo,
1997; Hocking et al., 1998). The prototype member of
the leucine-rich repeat proteoglycans is decorin which
has a core protein of about 36 kDa, either two or three
N-linked oligosaccharides and a single chondroi-
tin/dermatan sulfate chain in mammals. Decorin
received its name because it binds to the surface of
collagen fibrils, thus "decorating" the fibrils. In addi-
tion to binding to different types of collagen, it can
also interact with a variety of other ECM molecules,
such as fibronectin and thombospondin, as well as
with Clq and with different members of the TGF-I]
family. Whereas most of these interactions are medi-
ated by the core protein, the GAG chain is also able to
interact with other molecules, such as with heparin
cofactor II (Whinna et al., 1993). In spite of theseEXTRACELLULAR MATRIX AND CYTOKINES 93
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FIGURE Disaccharide units of different glycosaminoglycans and their modifications
many different interaotions, the decorin (-/-) mouse
exhibits only a mild phenotype with reduced tensile
strength of collagen fibrils from skin, suggesting that
decorin is only essential for the formation of func-
tional collagen fibrils in the skin, whereas in other
organs the lack of this proteoglycan can be compen-
sated, presumably by other members of the small leu-
cine-rich proteoglycan family (Danielson et al.,
1997). More recently it has been shown that decorin
can bind to the EGF receptor which, after phosphor-
ylation, causes an up-regulation of p21WAF-1/CIP-1
and growth arrest in tumor cells, suggesting a further
role for decorin in growth control (Moscatello et al.,
1998). Apparently, this observation is not restricted to
tumor cells, as endothelial cells induced to express
decorin by infection with a replication deficient aden-
ovirus containing the human decorin cDNA show a
similar up-regulation of this inhibitor of cyclin
dependent kinases (E. Sch6nherr, unpublished result).
The closest relative of decorin is biglycan, which,
however, can carry either one or two chondroitin/der-
matan sulfate chains due to the presence of a second
GAG attachment site. Biglycan, too, can interact with
several types of collagen as well as with TGF-. As
decorin can compete with the binding of biglycan to
collagen type I fibrils (Sch6nherr et al. 1995) and to
TGF-I (Hildebrand et al., 1994), apparently both pro-
teoglycans interact with the same or very close bind-
ing site on these molecules. In addition, both
proteoglycans compete for the same binding site on
the decorin/biglycan endocytosis receptor (Hausser et
al., 1998). Core protein-mediated binding to this
receptor, which additionally interacts with heparan
sulfate chains (Hausser and Kresse, 1991; Hausser et
al., 1993), is the prerequisite for internalization and
subsequent intralysosomal degradation of decorin and
biglycan by mesenchymal cells. Even though there
are many similarities between these two small prote-
oglycans, the phenotype of the biglycan (-/-) mouse is
quite different from that of the decorin (-/-) mouse. In
contrast to skin fragility as a consequence of lack of
decorin, lack of biglycan leads to osteoporosis (Xu et94 ELKE SCHONHERR and HEINZ-JIRGEN HAUSSER
al., 1998). Fibromodulin and lumican are two other
small leucine-rich repeat proteoglycans, which in
contrast to decorin and biglycan can carry keratan sul-
fate chains. They too bind to collagen type I fibrils,
albeit at different binding sites. Both, the fibromodu-
lin (-/-) mouse (Swensson et al,. 1999) and the lumi-
can (-/-) mouse (Chakravarti et al., 1998) have thinner
and disorganized collagen fibrils, indicating that
decorin, fibromodulin and lumican all are important
for collagen fibrillogenesis.
Another small matrix proteoglycan, which however
does not belong to the family of small leucine-rich
proteoglycans, is proteoglycan-100 (PG-100). This
chondroitin sulfate proteoglycan has been named
according to the apparent molecular mass of its core
protein (Schwarz et al., 1990). Later it was identified
as the proteoglycan form of macrophage-colony stim-
ulating factor (CSF-1, Price et al., 1992, Suzu et al.,
1992). PG-100 is synthesized by many different cells
like monocytes/macrophages (Chang et al., 1998),
endothelial cells (Nelimarkka et al., 1997) and oste-
oblasts (Felix et al., 1996). Many other cells have
been shown to synthesize CSF-1, but it has not been
determined whether the cytokine is released in its pro-
teoglycan form or in, its mature form, which is a
homodimer of 85 kDa. This homodimer is generated
by partial proteolysis of the C-terminus which con-
tains the GAG chain. It has not been clarified so far
whether this cleavage reaction occurs due to an auto-
catalytic activity of PG-100 itself, or whether other
proteases are involved in this step. Comparison of the
growth stimulatory effect of PG-100 and the mature
CSF-1 showed that the proteoglycan form is less
active (Partenheimer et al., 1995). Therefore, the pro-
teoglycan form could be a storage form of the
cytokine which is bound via its GAG chain to ECM
molecules (Suzu et al., 1992, Ohtsuki et al., 1993) and
which can be released by proteolytic degradation of
the matrix. In addition, the proteoglycan form but not
the mature form can bind FGF-2. Peptides of the core
protein of PG-100, which mediate this binding, can
inhibit the growth-stimulatory effect of FGF-2 (Suzu,
et al., 1997). It therefore appears that PG-100 is not
only a constituent of the ECM, but also a regulator of
cytokine action and, in its mature form, a cytokine by
itself.
THE EXTRACELLULAR REGULATION
OF TGF- ACTIVITY
The TGF- superfamily consists of a large number of
different polypeptide factors, comprising not only the
different TGF-[3s themselves, but also several bone
morphogenetic proteins and growth differentiation
factors. These molecules are involved in the regula-
tion of such diverse processes as cell proliferation,
differentiation, adhesion, migration and survival.
Three members of the TGF-[3 subfamily are found in
mammalian cells. However, most of the studies have
been done with TGF-I] and 2 (Massagu6, 1998). The
importance of TGF- 1 for the immune system has
become especially evident when TGF- (-/-) mice
were generated by targeted gene disruption. Only about
half of these mice were normally born and two weeks
after birth they developed a wasting syndrome with
multiple inflammatory lesions in almost all organs
without exposure to a pathogen, indicating an autoim-
mune reaction (Kulkarni et al., 1995; Boivin et al.,
1995). In contrast, all the TGF-I3 2 (-/-) mice died
perinatally and had multiple developmental defects
which did not overlap with the TGF-[ (-/-) mice,
indicating different functions of these two isoforms
during development (Sanford et al., 1997). This obser-
vation is even more interesting as the two isoforms,
when applied to cultured cells, very often lead to simi-
lar reactions, indicating that under cell culture condi-
tions important modulating factors are missing. These
factors may be in vivo supplied by components of the
surrounding extracellular environment of the cells.
The active form of the TGF-I3s is a disulfide-linked
homodimer. This molecule is synthesized in a
pre-pro-form. The pro-peptide is cleaved off before
secretion, but remains associated with the homodimer
as latency associated protein (LAP), thereby keeping
the molecule in a biologically inactive state. In addi-
tion, LAP mediates the binding to latent TGF[3 bind-
ing proteins (LTBPs) by disulfide bonds. Four
different LTBPs as well as two splice variants have
been identified so far. These multidomain glycopro-
teins belong to the fibrillin superfamily. They contain
epidermal growth factor (EGF)-like domains, most of
which are able to bind Ca2+, many cysteine-richEXTRACELLULAR MATRIX AND CYTOKINES 95
domains and hybrid motifs which contain features of
both domains (Sinha et al., 1998). LTBPs with or
without bound latent TGF-[3 complex can be cova-
lently crosslinked by transglutaminase reactions to
form fibrillar structures. In addition, they can be
bound to other proteins of the ECM like collagens and
fibronectin. In microfibrils, LTBPs have been found
associated with other members of the fibrillin super-
family. The exact mode of association with these
structures, however, is not known. In addition to
LTBPs, other proteins can bind LAR as e.g. a 140
kDa-protein which is homologous to chicken
cysteine-rich fibroblast growth factor receptor. This
molecule was found in CHO cells transfected with
TGF- 1, where the latent complex was in part associ-
ated with LTBP-1 and in part with this protein (Olofs-
son et al., 1997). The small leucine-rich repeat
proteoglycan fibromodulin, too, has been shown to
bind the TGF-[3 LAP complex (Hildebrand et al.,
1994). Apparently, this complex can associate with dif-
ferent structures within the ECM, leading to the tempo-
rary deposition of latent TGF- waiting for activation.
Activation of TGF-[3 in such complexes is very
likely achieved by limited proteolysis mediated by
serine proteases, like llasmin, thrombin, elastase or
chymase which degrade LAP and the associated pro-
teins to release activated TGF-, e.g. during ECM
remodeling (Munger et al., 1997). Another mode of
activation involves thrombospondin, which specifi-
cally binds LAR thus inhibiting the reformation of the
latent complex (Ribeiro et al., 1999). The integrin
Ov6 also can bind LAP and it has been shown that
cells expressing this integrin can activate TGF-[3
(Munger et al., 1999). In vitro, TGF- can be acti-
vated not only by proteases, but also by acid, alkali,
heat or glycosidases.
Signal transduction of TGF-[ requires sequential
binding of activated TGF-[3 to the type II and the type
I receptor to form a heterotetrameric complex which
has intracellular serine/threonine kinase activity. Two
other receptors for TGF- have been found on the cell
surface, betaglycan and endoglin (CD105). Appar-
ently, these receptors do not have a signaling func-
tion. Betaglycan is a so called part time proteoglycan
which can carry chondroitin and/or heparan sulfate
chains or no GAG chains at all. The core protein has
two separate binding sites for TGF-, one at the
N-terminus and the other at the C-terminus of the
extracellular domain (Kaname and Ruoslahti, 1996).
Bound TGF-, especially TGF-[32 can be presented to
the type II receptor (Lopez-Casillas et al., 1993). In
this way betaglycan can assist the two signaling
receptors in the formation of the active signal trans-
ducing complex. By shedding the extracellular
domain of this proteoglycan from the cell surface,
free soluble betaglycan may, on the other hand, func-
tion as a receptor antagonist which keeps TGF-[3
away from the signaling receptors (Lopez-Casillas et
al., 1994). The other accessory receptor, endoglin,
shares some sequence similarity with betaglycan. It
occurs on the cell surface as a disulfide linked dimer.
In contrast to betaglycan, this molecule only binds
TGF-[31 and 3 but not TGF-132 (Cheifetz et al., 1992).
In more recent studies differences between the two
assisting receptors in the presentation of TGF-[3 to the
signaling receptors have been shown, too. In a myob-
last system endoglin facilitates the binding of TGF-
to both the type I and type II receptors, whereas
betaglycan only assisted in binding to the type II
receptor (Letamendia et al., 1998). Whether this find-
ing is of general importance or specific for myoblasts,
remains to be determined.
Not only cell surface proteins and proteoglycans
but also molecules of the surrounding ECM can bind
active TGF-[3. Decorin, biglycan and fibromodulin all
have been shown to bind this cytokine (Hildebrand et
al., 1994). All these three small proteoglycans appear
to compete with betaglycan for the same binding site
on the TGF- dimer (Fukushima et al., 1993). How-
ever, the consequences of this interaction is still a
matter of debate. Whereas some investigators sug-
gested a direct inactivation of TGF-[ by decorin
(Yamaguchi and Ruoslahti, 1988; Yamaguchi et al.,
1990), others found no change in TGF-[3 activity
(Hausser et al., 1994) or even an activation of TGF-[3
(Takeuchi et al., 1994) due to complex formation with
decorin. One possible explanation for these conflict-
ing results in different experimental settings may be
further interactions with yet unidentified binding part-
ners which may modify the interaction of decorin,96 ELKE SCHI3NHERR and HEINZ-JRGEN HAUSSER
TGF- and the TGF-[3 receptors. It could be shown,
for instance, that decorin bound to collagen type I
fibrils is still able to bind TGF-[3 (Hausser et al., 1994,
Sch6nherr et al., 1998). This suggests that in vivo
decorin could inhibit TGF-[3 by immobilizing the
cytokine in the ECM, keeping it away from its signal-
ing receptors on the cell surface. This mechanism for
regulating TGF-[3 activity is further corroborated by
experiments showing that osteosarcoma cells
(MG-63) transfected with a decorin sense construct
and cultured in a collagen type I lattice exhibit a
reduced reactivity to TGF-[3 than the same cells trans-
fected with a decorin anti-sense construct, which
causes a lower expression of endogenous decorin (A.
Markmann, personal communication). Immobilized
TGF- might subsequently become "activated" by
partial proteolysis of decorin, as it has been shown
that decorin is a substrate for some metalloproteinases
(Imai et al., 1997), or by degradation of the collagen
matrix. Another possible binding partner is dermat-
opontin, an ECM constituent that has been shown to
bind decorin, collagen type I fibrils and TGF-. In a
recent study it could be demonstrated that dermat-
opontin can enhance the binding of TGF- to its cell
surface receptors, thus leading to an increased signal
transduction (Okamoo et al., 1999). Finally, an inter-
action of decorin with its endocytosis receptor
(Hausser et al., 1989) present at the cell surface of
many cells could be envisaged as a further possibility
for decorin to influence TGF- activity. If, for
instance, the decorin/TGF-[3 complex would be a sub-
strate for endocytosis, decorin could mediate the
clearance of extracellular TGF-I, thereby decreasing
its activity. Whether the decorin/TGF- complex is
able to bind to the endocytosis receptor has so far not
been investigated. However, the observation that
both, binding of decorin to its receptor and binding of
TGF- to decorin can be inhibited by an antibody
directed against the central region of the decorin core
protein (aa 155-260 of pre-pro decorin) argues for a
close spatial relationship of the two binding sites
(Hausser et al., 1998; Sch6nherr et al., 1998).
Not only the activity ofTGF- is affected by mole-
cules of the ECM, TGF-I3 itself has a profound effect
on the synthesis and degradation of a large number of
ECM molecules. A stimulation of the synthesis of
fibronectin, different types of collagen, thrombospon-
din, laminin, some proteoglycans, tissue inhibitors of
metalloproteinases, integrins etc. as well as the inhibi-
tion of the expression of metalloproteinases together
lead to an increased deposition of ECM (Massagu6,
1990). Such an increased ECM deposition by resident
and/or invading cells is necessary during wound heal-
ing (Sporn and Roberts, 1992). In chronic inflamma-
tion, however, excessive ECM synthesis can lead to
fibrosis with concomitant destruction of normal organ
function (Okuda et al., 1990; Border and Noble,
1994). Therefore, during the last decade strategies to
interfere with the TGF-[ mediated ECM deposition
have attracted a lot of interest. In this context the
TGF--binding small leucine-rich proteoglycans have
been discussed as potential therapeutics in fibrotic
diseases, as intravenous application of exogenous
decorin (Border et al., 1992) as well as a gene thera-
peutic approach with decorin cDNA (Isaka et al.,
1996) led to a reduction in TGF-[ mediated matrix
deposition and to an amelioration of the symptoms in
an acute model of mesangioproliferative glomerulone-
phritis. In addition to mere binding of TGF-, it has
been found recently that decorin can also abrogate the
expression of TGF-[31 and 2 (Stander et al., 1998). Fur-
thermore, these authors demonstrated that decorin can
lead to an increased invasion of B- and T-cells, in con-
trast to TGF-[3 which is a strong chemoatractant for
monocytes (Wahl et al., 1987). Such a change in the
type of the invading cells could change the whole char-
acter of the inflammation. Finally, by binding to
fibronectin, decorin could exert an antiadhesive effect
on invading cells (Winnem611er et al., 1991), thus
decreasing the population of cells that contribute to the
matrix deposition under the influence of TGF-13. Obvi-
ously, several different mechanisms could be involved
in mediating the antifibrotic activity of decorin.
FIBROBLAST GROWTH FACTOR-2 AND THE
ECM
Whereas most of the interactions of TGF-[ with the
ECM are mediated by proteins and the significance of
its interaction with heparan sulfate chains remain toEXTRACELLULAR MATRIX AND CYTOKINES 97
be elucidated, binding to heparan sulfate chains is of
outstanding importance for FGF-2. This cytokine
belongs to an ever increasing family of growth factors
with until now 18 known members (Fernig and Gal-
lagher, 1994; Ohbayashi et al., 1998). It plays part in
such important physiological processes as embryonic
development, angiogenesis, neuronal differentiation
and wound repair, being involved in the regulation of
migration, proliferation and differentiation of numer-
ous cell types. Even though it shares only 10%
sequence identity with interleukin 1, the tertiary
structure of these two molecules is identical (Zhang et
al., 1991). The relationship between the "growth fac-
tor" FGF-2 and "classical" cytokines, however, is not
only a structural one. In concert with other soluble
factors, it participates in positively regulating hemato-
poesis by acting on stromal cells as well as on early
and committed hematopoetic progenitors, preventing
apoptosis and leading to an increased cell prolifera-
tion and cytokine secretion (Allouche, 1995). This is
achieved by acting synergistically with numerous
hematopoetic cytokines as well as by antagonizing
the effects of TGF-I.
Members of the FGF family exert their biological
effects by binding t four structurally related
high-affinity FGF receptors (Friesel and Maciag,
1995; Klint and Claesson-Welsh, 1999). These
polypeptides contain an extracellular domain com-
posed of up to three immunoglubulin-like domains, a
transmembrane domain and an intracellular tyrosine
kinase domain. By alternative splicing, structural var-
iants are generated that differ in their ligand-binding
specificities and affinities. In addition to these
high-affinity signaling receptors, it has been recog-
nized for long time that FGF-2 (and the other mem-
bers of the FGF family) binds with lower affinity to
heparan sulfate chains present in the ECM and on the
cell surface. This interaction not only leads to a
sequestration of the cytokine within the ECM and to
its stabilization and protection from inactivation (Vlo-
davsky et al., 1996). It is also required for the
cytokine to exert its biological activity (Yayon et al.,
1991; Rapraeger et al., 1991).
The minimal binding structure on the heparan sul-
fate chain has been revealed to be a pentasaccharide
containing at least one iduronic acid residue sulfated
at C2 and one or two N-sulfate groups (Maccarana et
al., 1993; Faham et al., 1996). Additional sulfate
groups, either at C2 of iduronic acid or at C6 of glu-
cosamine, are not required for binding and do not
interfere with binding. For stimulation of the
mitogenic activity of FGF-2, however, a sequence of
at least 12 saccharides containing sulfate groups at C2
of iduronic acid as well as at C6 of glucosamine is
necessary (Guimond et al., 1993).
Different models have been discussed to explain
the activation of FGF-2 by interaction with heparan
sulfate: (1) binding of heparan sulfate leads to an
altered conformation of the cytokine, enabling it to
interact efficiently with its signaling receptor; (2)
binding of two FGF-2 molecules on the same heparan
sulfate chain facilitates receptor dimerization neces-
sary for signal transduction by presenting a "dimeric"
ligand and (3) formation of a ternary complex by
simultaneous binding of ligand and receptor to adja-
cent binding sites on the same heparan sulfate chain
(Turnbull and Gallagher, 1993; Salmivirta et al.,
1996). Indeed, the receptor has been shown to be able
to interact with heparan sulfate (Kan et al., 1993), and
this interaction can lead to an activation of the recep-
tor, even in the absence of cytokine (Gao and Gold-
farb, 1995). The observation of additional structural
requirements for activation in comparison with
FGF-2 binding alone is in support of the third model,
postulating the formation of a ternary complex as the
signaling complex. There are two important predic-
tions derived from this model: (1) depending on the
spacing of the two binding sites for receptor and
FGF-2 on the GAG chain, interaction of the cytokine
with heparan sulfate will either promote or inhibit its
cellular response and (2) the fine structure of the
heparan sulfate chain will determine which of the
heparin-binding cytokines will be activated, provided
that different cytokines possess different binding
requirements. Indeed, different fine structures appear
to be necessary for activation of FGF-1, FGF-2 and
FGF-4 (Guimond et al., 1993). Therefore, by chang-
ing the fine structures of their cell surface heparan
sulfates, cells may select the cytokine to be activated.
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heparan sulfate proteoglycans with newly synthesized
ones or by modification of the GAG chains during
recycling of proteoglycans (Fransson et al., 1995). In
the developing neuroepithelium, cell surface associ-
ated heparan sulfate proteoglycans carry chains that
are able to bind and activate FGF-2 on day 9 (Nur-
combe et al., 1993). Two days later, with the onset of
FGF-1 expression, the fine structure of newly synthe-
sized heparan sulfate chains is changed, allowing
binding and activation of FGF-1. At this time, the
more differentiated cells synthesize longer heparan
sulfate chains containing more modified domains
with a higher content of disaccharide units sulfated at
C2 of the iduronic acid and, importantly, at C6 of the
glucosamine residues (Brickman et al., 1998a; Brick-
man et al., 1998b). Sulfation at C6 of glucosamine
appears to be required for binding of FGF-1 (Fromm
et al., 1997).
Obviously, due to the fact that cytokine activation
requires the formation of a ternary complex of
cytokine, receptor and heparan sulfate, "activating"
heparan sulfate chains have to be in close proximity
of the receptor molecules. Therefore, chains of matrix
associated proteoglycans that are remote from the sig-
naling receptors will sequester the cytokine within the
ECM, actually leading to its inactivation, provided
they possess the appropriate binding structures. Upon
proteolytic degradation of the matrix or upon degra-
dation of the heparan sulfate chains by released
heparanases, these bound cytokines however may
become available for signaling. On the contrary,
cytokine bound to cell surface associated heparan sul-
fate proteoglycans may become inactivated due to the
shedding of the respective proteoglycan molecules,
either by proteolytic cleavage of a juxtamembraneous
cleavage site in the case of syndecans or by cleavage
of the GPI anchor in the case of the glypicans. Thus,
in addition to factors controlling release and degrada-
tion, a complex interplay involving the regulated syn-
thesis and distribution of heparan sulfate
proteoglycans as well as the regulated activities of
extracellular enzymes acting on these proteoglycans
determines the availability and biological activity of
heparan-sulfate binding cytokines.
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